Psoriasis

Last updated: March 10, 2026
Table Of Contents

Overview

Psoriasis is a common chronic inflammatory skin condition characterized by raised, red, itchy, scaly plaques on the skin. It is caused by an abnormal T-cell-mediated immune response. T-cells release cytokines, which lead to keratinocyte proliferation.

10-15% of cases are associated with psoriatic arthritis. It affects 2-4% of the population. Can affect any age but has 2 peaks of incidence at 15-25 years and 50-60 years. The condition is usually lifelong.

Types of psoriasis

TypeDescription
Classical psoriasis (typical or chronic plaque)Erythematous plaques without scales. Common in women, the elderly, and HIV positive. Difficult to differentiate it from eczema and diagnose as psoriasis due to its unusual distribution (submammary, axillary, anogenital, umbilical)
Guttate psoriasis (Raindrop lesions)Occurs in the young following streptococcal tonsillitis (acute guttate psoriasis). Has multiple discoid erythematous and scaly macules and plaques on the trunk. Smaller plaques of < 3cm in diameter.
Palmoplantar pustularHas yellow-brown pustules on palms and soles
Flexural (body folds)Erythematous plaques without scales. Common in women, the elderly, and HIV-positive individuals. Difficult to differentiate it from eczema and diagnose as psoriasis due to its unusual distribution (submammary, axillary, anogenital, umbilical)
Erythrodermic (total body redness)Acute onset of erythroderma and pustular plaques. It is an emergency. Managed with Methotrexate.
  • Risk factors for psoriasis
    • Genetic susceptibility
    • Smoking
    • Obesity
    • Psychological stressors
  • Precipitating factors
    • Trauma (Koebner’s phenomenon)
    • Infection (Tonsillitis)
    • Beta-Blockers, Lithium, Antimalarials, NSAIDs, and ACEIs
    • Emotional stress
    • Sunlight
    • Puberty
    • Menopause
    • Alcohol
  • Histopathology
    • Keratinocyte hyperproliferation (differentiation)
    • Parakeratosis (retained nuclei)
    • Acanthosis (thick epidermis)
    • Absent granular layer
    • Lengthened rete ridges
    • Thin dermal papillae
    • Dilated tortuous capillaries
    • Munro’s micro-abscesses
    • T-cells in the upper dermis
  • Common location of psoriasis – it can affect any part of the body
    • Scalp, especially behind the ears
    • Elbows
    • Knees
  • Signs and symptoms
    • Symmetrical, erythematous plaques with white/silver scaling often on extensor surfaces (front of knees, back of elbows)
    • Itching (accompanied by excoriation and lichenification in long-term, more severe cases)
    • Auspitz sign (capillary bleeding on scale removal)
    • Nail changes (50%): pitting, onycholysis (nail lifting off the bed), subungual hyperkeratosis, Beaus’ lines (horizontal lines across the nails)
  • Differential diagnosis of nail changes
    • Dermatitis (discoid or seborrhoeic)
    • Lichen planus
    • Pityriasis rosea (especially guttate psoriasis)
    • Secondary syphilis
    • Reiter’s syndrome (especially palmoplanar psoriasis)
    • Discoid lupus
    • Fungal infection
    • Alopecia areata
  • Conditions associated with psoriasis
  • Indications for referral to a dermatologist (specialist)
    • 10% of body surface area affected
    • Not responding to topical treatment
    • Psoriasis in children
    • Psoriasis having a major impact on psychological health
    • Associated mental illness e.g. Major Depressive Disorder, Anxiety secondary to their skin condition
  • Complications of psoriasis
    • Erythroderma
    • Psychological and Social Effects

Treatment of Psoriasis

Typical Regimen for the treatment of psoriasis

LineTreatment
1st lineVitamine D analogues +/- topical steroids + tar/salicylic acid +/- UVB
2nd lineRetinoids, PUVA, UVB, Immunosuppressants
3rd lineDithranol
Goekerman regimenTar + UVB
Ingram regimenGoekerman + Dithranol
  • Risk reduction (Lifestyle modification)
    • Smoking cessation
    • Reduce alcohol intake
    • Weight loss
    • Avoid long sunlight exposure
    • Manage stress (mental health)
  • Topical agents used to treat psoriasis
    • Emollients
    • Corticosteroids (Betamethasone 0.1%, Hydrocortisone 1%)
    • Vitamin D analogues (Calcipotriol, tacalcitol, calcitriol)
    • Corticosteroids + Vitamin D analogs (Daivobet, Enstillar foam)
    • Coal tar preparations
    • Dithranol
    • Keratolytics (Salicylic acid)
    • Retinoids (Tazarotene)
  • Systemic treatment of psoriasis
    • Phototherapy
      • UVB – classic and guttate psoriasis (Narrowband UVB has a low risk of burning and long-term sun damage) and is used before UVA
      • Photochemotherapy UVA (PUVA): used in combination with retinoids (to reduce the dose of PUVA) to treat cases not responsive to UVB. Associated with long-term skin damage and increased risk of cancer
    • Retinoids (Acitretin)
    • Immunosuppressants (Methotrexate, Cyclosporine, Azathioprine, Hydroxyurea)
    • Biological agents (Etanercept, adalimumab, infliximab)
  • Prognosis
    • Psoriasis has a variable course, and relapse is common
    • Poor prognostic factors include a strong family history and an early age of onset
    • Overuse of steroids can cause pustular flares, which can lead to serious systemic infections
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *